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ABSTRACT Background
The Iberian Peninsula stands out as having variable levels of population admixture and isolation, making Spain an interesting setting for studying the genetic architecture of neurodegenerative diseases.
Objectives
To perform the largest Parkinson disease (PD) genome-wide association study (GWAS) restricted to a single country.
Methods
We performed a GWAS for both risk of PD and age-at-onset (AAO) in 7,849 Spanish individuals. Further analyses included population-specific risk haplotype assessments, polygenic risk scoring through machine learning, Mendelian randomization of expression and methylation data to gain insight into disease-associated loci, heritability estimates, genetic correlations and burden analyses.
Results
We identified a novel population-specific GWAS signal at PARK2 associated with AAO. We replicated four genome-wide independent signals associated with PD risk, including SNCA, LRRK2, KANSL1/MAPT and HLA-DQB1. A significant trend for smaller risk haplotypes at known loci was found compared to similar studies of non-Spanish origin. Seventeen PD-related genes showed functional consequence via two-sample Mendelian randomization in expression and methylation datasets. Long runs of homozygosity at 28 known genes/loci were found to be enriched in cases versus controls.
Conclusions
Our data demonstrate the utility of the Spanish risk haplotype substructure for future finemapping efforts, showing how leveraging unique and diverse population histories can benefit genetic studies of complex diseases. The present study points to PARK2 as a major hallmark of PD etiology in Spain.
INTRODUCTION
Parkinson disease (PD) is a complex disorder arising from the interplay of polygenic risk, environment and stochastic factors occurring in an unpredictable manner 1 . Over the last 20 years, extensive work in molecular genetics has dissected the underlying genetic cause of several familial and early-onset patients in which disease was inherited in a Mendelian fashion.
However, while just a small percentage of PD cases are monogenic, often exhibiting variable penetrance, the vast majority are considered to be sporadic with complex genetic influence.
An important step forward in favor of a genetic contribution to the etiology of idiopathic PD has been taken from genome-wide association studies (GWAS). GWAS meta-analyses have been crucial to identifying and expanding the biological knowledge of novel disease risk factors. However, one of the main challenges is the heterogeneity across cohorts that might mask genetic associations specific to certain populations. Therefore, establishing population specific catalogues of genetic variation when studying the genetic basis of PD is necessary.
Separated from the rest of Europe by the Pyrenees range of mountains and just 700 miles from the North coast of Africa, the Iberian Peninsula represents a cross-link between two continents and stands out as having remarkably variable levels of admixture, which has been reinforced by linguistic and geopolitical boundaries within the territory 4 . The Spanish population has a more diverse haplotypic structure in comparison with other European populations and is somehow isolated within itself in terms of global genetic structure 5 . The long-lasting migratory influences since early centuries and ulterior admixture from a number of civilizations over recent history have left their genetic imprint, thereby creating a particular genome population structure and diversity 6 . Taken together, these observations make Spain an interesting setting to comprehensively study the genetic architecture of PD and other complex diseases.
Here, we have performed the largest PD genome-wide assessment from a single country to date, by characterizing 7,849 Spanish individuals. We compared our new Spanish dataset with extant data from various European ancestry populations to relate our findings in the context of larger studies. We also analyzed risk profiles, heritability and autozygosity in this population as it relates to PD etiology. Of particular interest are our analyses leveraging the unique population genetic structure of Spain to identify smaller risk haplotype blocks than in less admixed
Europeans. We envisage that the data generated from this large study, together with other concomitant efforts underway in other European populations, will be key to shed light on the molecular mechanisms involved in the disease process and might pave the way for future therapeutic interventions. 
METHODS

Cohort characteristics
Genome-wide association study versus Parkinson disease, age at onset and risk haplotype structure
To estimate risk associated with PD, imputed dosages were analyzed using a logistic regression model adjusted for sex, AAO for cases or examination for controls and the first 20 PCs as covariates. Summary statistics were generated using the RVTESTS package 9 and filtered for inclusion after meeting a minimum imputation quality of 0.30 and minor allele frequency greater than 1 %. To explore the influence of genetic variation on the AAO of PD cases, a linear regression model, adjusted for the same covariates, was performed (using AAO as the outcome instead of as a covariate).
Given the history of admixture in Spain, we hypothesized that there might be smaller haplotype blocks at risk loci than in less admixed populations 10 . We compared the size of the 90 independent risk haplotype blocks in Spanish cases with a British ancestry PD cohort composed of 1,478 cases. After standardizing both datasets with the same genotyped SNPs passing identical quality control in both datasets, we determined the size of the haplotype blocks in both populations by using PLINK 1.9
11
.
Whole genome sequencing analysis
To dissect the novel GWAS signal associated with AAO identified in the Spanish population, we performed whole genome sequencing analyses in 5 out of 37 homozygous carriers of the PARK2 
Genetic risk profiling
Polygenic risk score analysis for PD and AAO was performed as described in detail elsewhere 12, 13 . Briefly, a cumulative genetic risk score was calculated by using the R package PRSice2 14 .
Permutation testing and p-value after LD pruning was used to identify best P thresholds in external GWAS data (training dataset derived from summary statistics from Nalls et al. 2019
2 , excluding Spanish samples) to construct the PRS, allowing us to utilize variants below the common GWAS significance threshold of 5E-08. LD clumping was implemented under default settings (window size = 250kb, r 2 > 0.1) and using the Spanish dataset (testing dataset), 10,000
permutations were applied to generate empirical P estimates derived P threshold ranging from 5E-08 to 0.5, at a minimum increment of 5E-08. Each permutation test provided a Nagelkerke's pseudo r 2 after adjustment for an estimated prevalence of 0.5%, study-specific eigenvectors 1-20, AAO for cases or examination for controls and sex as covariates. GWAS derived P threshold with the highest pseudo r 2 was selected for further analysis.
Machine Learning to predict disease status
Summary statistics from the most recent meta-analysis excluding Spanish cohort samples 2 were used for initial SNP selection in our Machine Learning (ML) analyses. This analysis utilizes an upcoming software package (GenoML, https://genoml.github.io), an automated Machine
Learning tool that optimizes basic machine learning pipelines for genomic data. We used PD GWAS full summary statistics in the ML feature selection process from which we removed samples present in the Spanish PD cohort to avoid any circularity. Prior to analyses, we filtered the Spanish cohort genotype data for MAF > 1% and imputation quality > 0.8. Next, we randomly sampled without replacement 70% of the subjects for training the classifier and the other 30% for its validation. We opted to use PRSice 14 to pre-filter variants under default settings yielding 1,521 candidate variants from GWAS at a p-value threshold of 0.0005. In both the training and test sets, the dosage of each of the 1,521 variants per individuals is weighted by the GWAS beta. We then used a Caret ML [https://github.com/topepo/caret] framework with glmnet, xgbTree, xgbDART, xgbLinear and Random forest, with a grid search size of 30-and 10-fold cross validation on the training set. The algorithm maximizing mean area under the curve across iterations of cross-validation in the training set was then fit to the validation set to generate predictions and summary statistics.
Heritability estimates and genetic correlations
The heritability of PD in the Spanish population was calculated using Linkage Disequilibrium Score Regression (LDSC) 15 . This method has the ability to detect the contributions to disease risk of variants which do not reach genome significance but does not identify the specific variants contributing to disease risk. Using the same software, genetic correlations between PD and other catalogued GWAS studies were evaluated. The database, LD Hub, was used to screen overlapping genetic etiologies across 757 diseases/traits gathered from publicly available resources 15 . Default settings were used in the analyses and final results were adjusted for multiple testing by using Bonferroni correction.
Runs of homozygosity
Based on LD-pruned dataset (using previously described parameters), runs of homozygosity (ROHs) were defined using PLINK 1.9 11 . We explored ROHs containing at least 10 SNPs and a total length ≥ 1000 Kb, with a rate of scanning windows of at least 0.05 (not containing > 1 heterozygous call or 10 missing calls). In order to explore overall homozygosity between cases and controls, three metrics were assessed, including the number of homozygous segments spread across the genome, total kilobase distance spanned by those segments, and average segment size (autosomes only). Subsequently, ROHs were further investigated for known PD risk gene regions (Supplementary Table 2 ) and PD significant loci from GWAS 2 with a window of +/-1 Mb upstream or downstream. In these analyses, cryptically related PD individuals removed in previous steps were included to identify overrepresented sharing of recessive regions among cases.
Burden analyses
We examined the contribution of rare variation on disease risk by collapsing the cumulative effect of multiple genetic variants at a per-gene level. We performed the Sequence Kernel Association Test (SKAT) in imputed data after classifying variants into nested categories (based on two maximum minor allele frequency thresholds, (a) < MAF 1% or (b) < MAF 5%, and three functional filters, (1) 19 were considered possible exposures in the MR models. These include estimates for methylation and cis-expression across multiple brain regions 20 . We also studied expression patterns in blood from the meta-analyses as described 21 . Multi-SNP Summary-data-based MR was utilized to generate association estimates via MR between each QTL and local PD risk SNPs that contained 2 or more SNPs under default settings 19 . The current Spanish dataset was used as a reference for linkage disequilibrium in this analysis. For each reference QTL dataset, p-values were adjusted by false discovery rate.
Known genetic factors in Parkinson disease and atypical parkinsonism related genes
Considering both related and unrelated samples, we screened for relevant variants in known PD or parkinsonism-related genes. Our criteria included variants tagged as "disease causing mutation", "possibly disease causing mutation", "probably disease-associated polymorphism", "disease-associated polymorphism with additional supporting functional evidence", "pathogenic"
or "possibly pathogenic" in ClinVar 22 or Human Gene Mutation Database 23 . We followed two models: a putative dominant model (either the allele is present only in cases and absent in controls or with a lower frequency in controls) and a putative recessive model (two copies of the allele present only in cases and absent or with a lower frequency in controls). Genes screened are highlighted in Supplementary Table 2 . We further screened putative structural genomic variation associated with PD in PARK2 and SNCA, since notable genomic arrangements have been detected in these genes 24, 25 . Two metrics were assessed and visualized with R version 3.5.1 26 : B allele frequency and log R ratio. These two statistics allow visualization of copy number changes and are described in detail elsewhere 27 .
RESULTS
Genome-wide association for Parkinson disease risk, age at onset and population-specific risk haplotype structure analyses
We identified four genome-wide independent signals associated with PD risk, including SNCA, (Figure 1, Table 1, Supplementary Figure 2) .
LRRK2, KANSL1/MAPT and HLA-DQB1
Additionally, we show trends for association at an uncorrected p-value < 0.05 with 39 of the 90 loci previously identified in the largest PD meta-analysis performed to date 2 (Supplementary Table 3 ).
GWA for AAO of PD revealed a genome-wide significant association signal at PARK2 
Genetic risk profiling versus disease and age-at-onset
After adjusting for appropriate covariates and estimated PD prevalence, an overall pseudo r 2 between PRS and PD was approximately r 2 =0.026. For each standard deviation from the population mean of the PRS, risk was estimated to be an odds ratio of 1.667 (beta = 0.511, se = 0.027, p-value = 3.63E-79, empirical P after permutation 1.00E-4). This model incorporated a total of 665 SNPs up to p-value < 5.99E-05 in the current GWAS (Figure 3A-B) .
Similar models were generated for AAO. We observed an association between a one standard deviation increase in the age at onset polygenic score and a near one year earlier onset of disease 
Machine learning to predict disease status
The xgbDART algorithm 28 (extreme gradient boosting approach with additive linear regression trees regularized by drop-out) yields the best AUC as predictor of the probability PD in this Spanish GWAS cohort. The model in the validation set had an AUC of 0.6205 with a sensitivity and specificity of 0.86 and 0.24. This is a ~1% improvement over using simply polygenic risk scores prediction with PRSice alone, even after employing a two-stage design compared to a previous single phase that could be more overfit than what is presented here.
Heritability estimates and genetic correlations
SNP heritability estimates by LDSC were estimated to be 28.67 % ± 6.65%. We analyzed crosstrait genetic correlations between PD and 750 other GWAS datasets of interest curated by LD hub 15 . No genetic correlations remained significant after adjusting for multiple testing via false discovery rate. However, when considering an un-adjusted p-value < 0.05, negative correlations were found for body mass index related traits, smoking and alcohol intake, and positive correlations were identified for allergies and physical activity, among others (Supplementary Table 5 ).
Runs of homozygosity
PD cases in our dataset were shown to have longer ROHs than controls, both with regard to the percentage of the genome within these runs and the average run size. For every 10 Mb increase in ROHs per sample, we noted an odds ratio of 1.02 (beta = 0.02, se = 0.008, p-value = 0.0097), a small but significant increase. Average run size was also associated with PD risk at an odds ratio of 1.244 per 1 Mb increase in average run size (beta = 0.218, se = 0.068, p-value = 0.0013).
The total numbers of these ROHs were not significantly different between cases and controls.
This suggests that fewer large ROHs might be more closely associated with disease risk than many small ROHs.
We further explored extended runs of homozygosity in known Mendelian PD genes (Supplementary Table 2 ) and the 90 nominated risk loci in the last meta-analysis 2 .
Homozygosity was found enriched in cases versus controls at 28 genes/loci (Supplementary Table 6 ). However, only a ROH in PARK2 surpassed Bonferroni correction (p-value threshold = 0.001).
Burden analyses
We explored the cumulative effect of multiple rare variants at a gene level by grouping them in different categories based on frequency and functionality. We found a significant enrichment of coding variants in the LRRK2 gene in PD cases compared to controls (p-value = 4.51E-16).
When we excluded p.G2019S carried by 2.8% of the PD subjects from the analysis, the risk of PD conferred by LRRK2 is not significant (p-value=0.0611), suggesting that this variant is the main driver of the association. Rare coding variants in PARK2 were found overrepresented in cases versus controls (p-value = 0.008), although the association did not surpassed Bonferroni correction (p-value threshold = 0.0002). When focusing only on non-coding variants, GBA displayed an association at a p-value = 0.0003 which in this case did not reach multiple testing correction (p-value threshold = 3.15E-6). Finally, when grouping the variants by CADD score, we did not find any prospective novel gene associated with PD in the Spanish population.
Quantitative trait loci Mendelian randomization
After adjustment for false discovery rate, 17 PD-related genes/loci showed functional consequence via two-sample Mendelian randomization in expression and methylation datasets (Supplementary Table 7 Furthermore, the previously reported p.Asn613del in MAPT was identified in a 87 year old patient with an onset of rest tremor at 62 years and a notable family history of PD and progressive supranuclear palsy 29 . Finally, fourteen variants were found in four atypical parkinsonism-related genes, including FBXO7 and POLG1 (autosomal recessive), as well as ATP13A2 and DCTN1 (autosomal dominant), however, their disease significance is uncertain.
DISCUSSION
As part of a Spanish multicenter massive collaborative effort, we have gathered the largest collection of PD patients and controls from a single country to comprehensively assess the genetics of PD on a genome-wide scale. We have used the same genotyping platform, thus reducing possible batch effects. Here, we dissect population-specific differences in risk and AAO from a genetic perspective and highlight the utility of the Spanish risk haplotype substructure for future fine-mapping efforts.
In concordance with other populations 2 , our Spanish GWAS on PD risk replicated four loci Importantly, we revealed an overall excess of homozygosity in PD cases versus controls and identified 28 genes/loci exhibiting ROH overrepresented in cases, pointing out the possible existence of disease-causing recessive variants that might be uncovered by future sequencing analysis. Additionally, burden analysis reinforced the contribution of both common and rare variants in LRRK2, making Spain an important candidate population for specific LRRK2 clinical trials. In an effort to explore functional consequences associated to PD risk in the Spanish population, we performed quantitative trait loci Mendelian randomization analyses using expression and methylation data and suggest biological pathways underlying the nominated genes warrant further study.
Recent research has begun to demonstrate the utility of polygenic risk profiling to identify individuals who could benefit from the knowledge of their probabilistic susceptibility to disease, an aspect that is central to clinical decision-making and early disease detection 32 . Here, we assessed the overall cumulative contribution of common SNPs on disease risk and age at onset.
Our PRS derived model for disease risk and age at onset showed expected trends comparable to previous literature 12, 13, 33 .
While we have made progress in assessing genetic risk factors for PD in a population-specific manner, there are a number of limitations to our study. First, although all the available PD cases and controls from Spain have been assessed, we are aware of the caveats driven by sample size.
Dissection of additional susceptibility genetic risk and phenotypic relationships would have been possible if a larger cohort had been analyzed. In fact, the heritability estimate, of ~ 28.67 % in this population, indicates that there is a large component of genetic risk yet to be uncovered. We assume there are a considerable number of variants that impact risk for disease outside the limits of what can be accurately detected with a genotyping platform. This could explain the lower observed frequency of certain well-established pathogenic variants and exonic rearrangements when comparing other sequencing studies previously performed in the Spanish population 33,34. We have applied a state-of-the-art machine learning approach in an effort to predict disease status. Our results show that genetic data are not sufficient to accurately predict disease status in a clinical setting by itself when used alone, although this may change in the future when combining genetic with other biomarker data. Entering the era of personalized medicine in which an individual's genetic makeup will help determine the most suitable therapy, we envisage our collaborative initiative will expand towards identifying, refining, and predicting heritable risk in the Spanish population by combining future large-scale whole-genome sequencing approaches, multi-omics and detailed longitudinal clinical data for translational approaches. We conclude by saying that this is the starting point of a collaborative network of Spanish clinicians and scientists that will continue to pave the road towards future therapeutic interventions. 
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